Clinical Trial Update: Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Ivonescimab in combination with liposomal irinotecan and 5-FU/leucovorin for potentially resectable biliary tract cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• 5-FU/LV (5-fluorouracil with leucovorin)
• Ivonescimab (AK112/SMT112)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Biliary Tract Cancer | Phase 2 | Status: NOT_YET_RECRUITING